Vanda Pharmaceuticals (VNDA) Payables (2010 - 2026)

Vanda Pharmaceuticals has reported Payables for 17 years, with the latest figure at $60.6 million in Q1 2026.

• Quarterly Payables rose 33.88% year-over-year to $60.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.6 million (up 33.88% YoY) and the FY2025 annual result came in at $68.3 million, up 74.74% from the prior year.
• Payables retreated to $60.6 million in Q1 2026 per VNDA's latest filing, from $68.3 million in the prior quarter.
• Over five years, Payables peaked at $68.3 million in Q4 2025 and troughed at $31.9 million in Q2 2023.
• A 5-year average of $45.3 million and a median of $45.3 million in 2025 frame the typical range for Payables.
• The sharpest annual moves came in 2022 and 2023: Payables soared 96.87% in 2022, then tumbled 36.44% in 2023.
• Over 5 years, Payables stood at $45.6 million in 2022, then dropped by 15.57% to $38.5 million in 2023, then grew by 1.63% to $39.1 million in 2024, then soared by 74.74% to $68.3 million in 2025, then retreated by 11.24% to $60.6 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $60.6 million, $68.3 million, and $47.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.